József Knoll Explained
József Knoll (May 30, 1925 – April 17, 2018), or Joseph Knoll, was a Hungarian psychopharmacologist known for developing the antiparkinsonian and antidepressant drug selegiline (L-deprenyl).[1] [2] [3] [4]
He developed selegiline in the 1960s and subsequently studied the drug and related agents for many decades. Knoll also developed the concepts of monoaminergic activity enhancers (MAEs) and the mesencephalic enhancer regulation system, among other contributions. MAEs developed by Knoll and colleagues include selegiline, benzofuranylpropylaminopentane (BPAP), and phenylpropylaminopentane (PPAP), among others.
During his scientific career, Knoll published 894papers and was the originator of 55patents. As of 2018, his papers had been cited more than 10,000times. He is described as one of the best-known Hungarian pharmacologists.
Knoll is known for having extensively researched and promoted selegiline for claimed drive- and longevity-enhancing effects related to its MAE activity. Knoll himself began taking a low 1mg daily dose of selegiline on January 1, 1989 at the age of 64.[5] He reported in 2012 that this had continued for 22years uninterrupted. Knoll stated that he had become so fascinated with the possible longevity-promoting effects of selegiline he was studying that he had decided to start taking it as a self-experiment. Knoll later died in 2018 at the age of 93.[6]
Selected publications
Books
- Book: Knoll J . The Brain and Its Self: A Neurochemical Concept of the Innate and Acquired Drives . Springer-Verlag . Berlin/Heidelberg . 2005 . 978-3-540-23969-7 .
- Book: Knoll J . How Selegiline ((-)-Deprenyl) Slows Brain Aging . Bentham Science Publishers . 2012 . 978-1-60805-470-1 . 4 July 2024 .
Reviews
- Knoll J . Antiaging compounds: (-)deprenyl (selegeline) and (-)1-(benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective highly potent enhancer of the impulse propagation mediated release of catecholamine and serotonin in the brain . CNS Drug Rev . 7 . 3 . 317–45 . 2001 . 11607046 . 6494119 . 10.1111/j.1527-3458.2001.tb00202.x .
- Knoll J . Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives . Neurochem Res . 28 . 8 . 1275–1297 . August 2003 . 12834268 . 10.1023/a:1024224311289 .
External link
Notes and References
- Miklya I . The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015) . Mol Psychiatry . 21 . 11 . 1499–1503 . November 2016 . 27480491 . 10.1038/mp.2016.127 .
- Book: Healy D . David Healy (psychiatrist). The Psychopharmacologists, Vol. III: Interviews . Arnold . London . 2000 . 81–110 . 10.4324/9781003058892-3 . 978-0-340-76110-6 . The Psychopharmacology of Life and Death. Interview with Joseph Knoll. .
- Web site: Ildiko Miklya . In Memoriam: Joseph Knoll (1925 – 2018) . September 20, 2018 . International Network for the History of Neuropsychopharmacology (INHN) . 15 August 2024 . He was one of the internationally best known Hungarian pharmacologists [...] He described the details of his work published with his pupils in 894 papers (citations: 10,055) and was the originator of 55 patents..
- Web site: Thomas A. Ban . In Memory of Joseph Knoll (1925 – 2018) . November 8, 2018 . International Network for the History of Neuropsychopharmacology (INHN) . 15 August 2024.
- Book: Knoll J . How Selegiline ((-)-Deprenyl) Slows Brain Aging . Bentham Science Publishers . 2012 . 978-1-60805-470-1 . 4 July 2024 .
- Ferdinandy P, Yoneda F, Muraoka S, Fürst S, Gyires K, Miklya I . Geroprotection in the future. In memoriam of Joseph Knoll: The selegiline story continues . European Journal of Pharmacology . 868 . 172793 . February 2020 . 31743738 . 10.1016/j.ejphar.2019.172793 . 208185366 .
